検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB1293 : SSP-25  update : 2022/03/31
細胞特性(Comment:英)Human intrahepatic cholangiocarcinoma. Please read carefully this information before use.
細胞特性(日)ヒト肝内胆管癌細胞株。必ずお読みください。
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
使用条件(日)基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。
備考(英)
備考(日)
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Enjoji, Munechika
樹立者 Enjoji, Munechika
寄託日 1996
動物種 human < Mammals
属名 Homo
種名 sapiens
人種 Japanese
性別 Female
採取組織 liver
病名 cholangiocarcinoma
細胞分類 cancer
細胞寿命 infinite
細胞形態 fibroblast-like
Cellosaurus(Expasy) CVCL_4902
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培地 RPMI1640 + 10% FBS
抗生物質 Free
継代方法 0.25% Trypsin
継代密度 1 : 8 split
継代・培地交換頻度 Subculture : once/week, Medium Renewal : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
ウィルス(HBV) (-)
ウィルス(HCV) (-)
アイソザイム検査 LD, NP
染色体検査 57-64(50) : /58(2),59(3),60(27),61(6),62(8),63(2)/
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 0件
Reference(日) 0件
利用者成果(英) 35件
利用者成果(日) 0件

トップへページトップへ
Reference(英)

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)
21103  Shi L, Shen W, Davis MI, Kong K, Vu P, Saha SK, Adil R, Kreuzer J, Egan R, Lee TD, Greninger P, Shrimp JH, Zhao W, Wei TY, Zhou M, Eccleston J, Sussman J, Manocha U, Weerasekara V, Kondo H, Vijay V, Wu MJ, Kearney SE, Ho J, McClanaghan J, Murchie E, Crowther GS, Patnaik S, Boxer MB, Shen M, Ting DT, Kim WY, Stanger BZ, Deshpande V, Ferrone CR, Benes CH, Haas W, Hall MD, Bardeesy N.  SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers.  Nat Cancer  2023    PubMed ID: 36914816   DOI: 10.1038/s43018-023-00523-0
21205  Mohan A, Griffith KA, Wuchu F, Zhen DB, Kumar-Sinha C, Crysler O, Hsiehchen D, Enzler T, Dippman D, Gunchick V, Achreja A, Animasahun O, Choppara S, Nenwani M, Chinnaiyan AM, Nagrath D, Zalupski MM, Sahai V.  Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04).  Clin Cancer Res  2023    PubMed ID: 37115501   DOI: 10.1158/1078-0432.CCR-23-0036
20420  Chui NN, Cheu JW, Yuen VW, Chiu DK, Goh CC, Lee D, Zhang MS, Ng IO, Wong CC.  Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.  Hepatol Commun  2022    PubMed ID: 34558800   DOI: 10.1002/hep4.1682
20893  Jamnongsong S, Kueanjinda P, Buraphat P, Sakornsakolpat P, Vaeteewoottacharn K, Okada S, Jirawatnotai S, Sampattavanich S.  Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma.  iScience  2022  25(10):105182  PubMed ID: 36248745   DOI: 10.1016/j.isci.2022.105182
21148  Kosai-Fujimoto Y, Itoh S, Yugawa K, Fukuhara T, Okuzaki D, Toshima T, Harada N, Oda Y, Yoshizumi T, Mori M.  Impact of JMJD6 on intrahepatic cholangiocarcinoma.  Mol Clin Oncol  2022  17(2):131  PubMed ID: 35911665   DOI: 10.3892/mco.2022.2564
13539  Nagaoka K, Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK.  Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis  Dig Dis Sci  2021  66(4):1080-1089  PubMed ID: 32445050   DOI: 10.1007/s10620-020-06330-2
14929  Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, Fujimoto M, Uemura S, Namikawa T, Murakami I, Kobayashi S, Eguchi H, Doki Y, Hanazaki K, Naka T.  Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1 positive cholangiocarcinoma  Mol Cancer Ther  2021  molcanther.0015.2021  PubMed ID: 34224365   DOI: 10.1158/1535-7163.MCT-21-0015
15502  Weng SW, Liu TT, Eng HL, You HL, Huang WT.  Autophagy Plays a Role in the CUL4A-Related Poor Prognosis of Intrahepatic Cholangiocarcinoma  Pathol Oncol Res  2021  27:602714  PubMed ID: 34257560   DOI: 10.3389/pore.2021.602714
12014  Somchai P, Phongkitkarun K, Kueanjinda P, Jamnongsong S, Vaeteewoottacharn K, Luvira V, Okada S, Jirawatnotai S, Sampattavanich S.  Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors.  Sci Rep  2020    PubMed ID: 31969633   DOI: 10.1038/s41598-020-57806-0
13336  Pan YR, Wu CE, Yeh CN.  ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.  Biomolecules  2020    PubMed ID: 33182492   DOI: 10.3390/biom10111529
12588  Yoh T, Hatano E, Kasai Y, Fuji H, Nishi K, Toriguchi K, Sueoka H, Ohno M, Seo S, Iwaisako K, Taura K, Yamaguchi R, Kurokawa M, Fujimoto J, Kimura T, Uemoto S, Nishi E.  Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection  Clin Cancer Res  2019  25(2):619-628  PubMed ID: 30352908   DOI: 10.1158/1078-0432.CCR-18-0124
12589  Miyata T, Yamashita YI, Yoshizumi T, Shiraishi M, Ohta M, Eguchi S, Aishima S, Fujioka H, Baba H.  CXCL12 expression in intrahepatic cholangiocarcinoma is associated with metastasis and poor prognosis  Cancer Sci   2019  110(10):3197-3203  PubMed ID: 31361379   DOI: 10.1111/cas.14151
14816  Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma  Cancer Discov  2019  9(8):1064-1079  PubMed ID: 31109923   DOI: 10.1158/2159-8290.CD-19-0182
11220  You HL, Liu TT, Weng SW, Chen CH, Wei YC, Eng HL, Huang WT.  Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma.  Oncol Lett  2018    PubMed ID: 30250623   DOI: 10.3892/ol.2018.9284
4347  Lin HY, Tey SL, Ho Y, Chin YT, Wang K, Whang-Peng J, Shih YJ, Chen YR, Yang YN, Chen YC, Liu YC, Tang HY, Yang YS.  Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-β Pathway.  Mar Drugs  2018    PubMed ID: 30563284   DOI: 10.3390/md16120489
14913  Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.  Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity  Dis Model Mech  2018  11(8):dmm03305  PubMed ID: 29666220   DOI: 10.1242/dmm.033050
10290  Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.  High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.  Mol. Carcinog.  2017  56:2146-2157  PubMed ID: 28467612   DOI: 10.1002/mc.22671
10333  Huang G-, Liu TT, Weng SW, You HL, Wei YC, Chen CH, Eng HL, Huang WT.  CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma.  BMC Cancer  2017  17:395  PubMed ID: 28576144   DOI: 10.1186/s12885-017-3389-z
10501  Kushibiki T, Noji T, Ebihara Y, Hontani K, Ono M, Kuwabara S, Nakamura T, Tsuchikawa T, Okamura K, Ishizuka M, Hirano S.  5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice.  In Vivo  2017  31:905-908  PubMed ID: 28882957   DOI: 10.21873/invivo.11145
9871  Hoshino H, Ohta M, Ito M, Uchimura K, Sakai Y, Uehara T, Low S, Fukushima M, Kobayashi M.  Apical membrane expression of distinct sulfated glycans represents a novel marker of cholangiolocellular carcinoma.  Lab. Invest.  2016  96:1246-1255  PubMed ID: 27748735   DOI: 10.1038/labinvest.2016.104
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123   DOI: 10.1158/2159-8290.CD-15-1442
5025  Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamoto A, Ishiko T, Beppu T, Baba H.  Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer.  Cancer Sci  2015  106(9):1153-62  PubMed ID: 26132727   DOI: 10.1111/cas.12732
9170  Sheng-Huei Yang 1, Hung-Yun Lin, Vincent H S Chang, Chien-Chung Chen, Yun-Ru Liu, Jinghan Wang, Keqiang Zhang, Xiaoqing Jiang, Yun Yen  Lovastatin Overcomes Gefitinib Resistance Through TNF-α Signaling in Human Cholangiocarcinomas With Different LKB1 Statuses in Vitro and in Vivo  Oncotarget  2015  6 (27), 23857-73  PubMed ID: 26160843   DOI: 10.18632/oncotarget.4408
15203  Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y.  Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma  Oncotarget  2015  6(22):18905-20  PubMed ID: 26056085   DOI: 10.18632/oncotarget.4305
12541  Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.  ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma  Hepatol Res  2014  44(14):E320-34  PubMed ID: 24552196   DOI: 10.1111/hepr.12312
12544  Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T.  Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma  Hepatol Res  2013  43(9):959-69  PubMed ID: 23369163   DOI: 10.1111/hepr.12047
8365  Ishii T, Yasuchika K, Suemori H, Nakatsuji N, Ikai I, Uemoto S.  Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma.  Cancer Lett.  2010  294:25-34  PubMed ID: 20149523   DOI: 10.1016/j.canlet.2010.01.019
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x
3575  Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T.  Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma.  Hepatology  2008  47(3):888-96  PubMed ID: 18306229   DOI: 10.1002/hep.22125
3335  Yoshino K, Iimura E, Saijo K, Iwase S, Fukami K, Ohno T, Obata Y, Nakamura Y.  Essential role for gene profiling analysis in the authentication of human cell lines.  Hum Cell  2006  19(1):43-8  PubMed ID: 16643607   DOI: 10.1111/j.1749-0774.2005.00007.x
3077  Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T  Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.  Mol Cancer Ther  2005  4:399-412  PubMed ID: 15767549   DOI: 10.1158/1535-7163.MCT-04-0234
3334  Obama, Kazutaka, Ura, Katsuaki, Satoh, Seiji, Nakamura, Yusuke, Furukawa, Yoichi  Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma  Oncol Res  2005  14:701-706  PubMed ID: 16077978  
3346  Yokoo, Hideki, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Todo, Satoru, Hirohashi, Setsuo  Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells.  Hepatology  2004  40:609-17  PubMed ID: 15349899   DOI: 10.1002/hep.20372
3703  Sanada T, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J.  Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers.  Cancer Sci  2004  95(12):969-76  PubMed ID: 15596046   DOI: 10.1111/j.1349-7006.2004.tb03185.x
15587  Tanaka S, Iwai M, Harada Y, Morikawa T, Muramatsu A, Mori T, Okanoue T, Kashima K, Maruyama-Tabata H, Hirai H, Satoh E, Imanishi J, Mazda O.  Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter  Cancer Gene Ther  2000  7(9):1241-50  PubMed ID: 11023196   DOI: 10.1038/sj.cgt.7700219

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ